Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer

BackgroundProgrammed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy has been approved as second-line or later therapy in advanced non-small-cell lung cancer (NSCLC). The study aimed to compare the clinical outcomes of PD-1 inhibitor plus chemotherapy with PD-1/PD-L1 inhibitor...

Full description

Bibliographic Details
Main Authors: Xiaoyang Zhai, Xuquan Jing, Ji Li, Yaru Tian, Shuhui Xu, Min Wang, Hui Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
non-small-cell lung cancer
PD-1
PD-L1
second-line or later therapy
immune-related adverse events
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.556275/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.556275/full

Similar Items